Premium
Rituximab‐induced interstitial lung disease in a patient with immune thrombocytopenia purpura
Author(s) -
Child N.,
O'Carroll M.,
Berkahn L.
Publication year - 2012
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2011.02701.x
Subject(s) - medicine , rituximab , interstitial lung disease , immune thrombocytopenia , refractory (planetary science) , complication , purpura (gastropod) , disease , lung , immunology , platelet , antibody , ecology , physics , astrobiology , biology
We report the case of an 84‐year‐old man with refractory immune thrombocytopenia purpura (ITP) who was treated with rituximab and subsequently developed severe interstitial lung disease. There has been increasing use of rituximab in the treatment of ITP with success rates of up to 62% in adult patients with recurrent ITP. Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP.